When should IL receptor antagonists be considered for asthma treatment?

IL receptor antagonists, such as monoclonal antibodies targeting interleukin receptors, are specifically designed to address underlying inflammatory pathways in asthma, particularly in patients with certain phenotypes. These medications are particularly beneficial for individuals with eosinophilic asthma, which is characterized by high levels of eosinophils, a type of white blood cell that plays a key role in the inflammation associated with asthma.

In cases of severe persistent asthma, where the disease is not adequately controlled by standard therapies like inhaled corticosteroids and long-acting bronchodilators, IL receptor antagonists can help reduce inflammation and improve control of the disease. They target the specific inflammatory process in eosinophilic asthma, leading to better management of symptoms, fewer exacerbations, and a reduction in dependence on oral corticosteroids.

In contrast, the other options suggest situations where IL receptor antagonists would not be appropriate. For instance, in mild intermittent asthma, the condition is usually well-controlled with rescue inhalers, and there is no need for more advanced therapy like IL receptor antagonists. As a first medication for all asthma patients, these agents are not suitable because asthma management typically begins with inhaled corticosteroids. Finally, using IL receptor antagonists only during exacerbations would not